Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02765828 · ClinicalTrials.gov registry record
Identification of Tongue Involvement in Late-Onset Pompe Disease
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 73
- Enrollment target
NCT02765828: Completed study, sponsored by Duke University.
NCT02765828 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02765828 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
Study Summary
This purpose of this study is to determine if tongue strength and tongue ultrasound measurements differentiates patients with untreated late-onset Pompe Disease (LOPD) from patients with acquires/hereditary myopathies or neuropathies. It is hypothesized that abnormalities in tongue function and structure in patients with LOPD may be useful in discriminating this condition from others that have similar presentations.
Primary Outcome
Lingual strength will be rated with a validated 0-4 ordinal scale. Score Description 0 - Normal strength, no weakness. 1. \- Mild weakness. The tongue can be overcome with effort. 2. \- Moderate weakness. Easy to overcome. 3. \- Minimal movement. Unable to protrude to either side. 4. \- No movement detected.
Interventions
- OTHER Observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2019-07-15 |
What the finished NCT02765828 record still lists
NCT02765828 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational study is the first listed.
NCT02765828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02765828 about?
NCT02765828 is a clinical study titled "Identification of Tongue Involvement in Late-Onset Pompe Disease". This purpose of this study is to determine if tongue strength and tongue ultrasound measurements differentiates patients with untreated late-onset Pompe Disease (LOPD) from patients with acquires/hereditary myopathies or neuropathies. It is hypothesized that abnormalities in tongue function and stru...
What is the current status of trial NCT02765828?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2016-05-25. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT02765828?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT02765828?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI